Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells

Cancer Immunology, Immunotherapy

Volumn 50, Issue 7, 2001, Pages 337-344

  Kikuchi, T ^a   Akasaki, Y ^a   Irie, M ^a   Homma, S ^a   Abe, T ^a   Ohno, T ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Astrocytomas; Dendritic cells; Fusion; Immunotherapy; Malignant gliomas

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; MACROGOL;

ADULT; ARTICLE; BLOOD; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUSION; CELL LINE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; EVALUATION; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; TARGET CELL;

ADULT; CELL FUSION; CHILD, PRESCHOOL; DENDRITIC CELLS; FEMALE; GLIOMA; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; T-LYMPHOCYTES; VACCINATION;

EID: 0034840181     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620100205     Document Type: Article

References (32)

1. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model
2. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo
3. Interleukin-12
4. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection
5. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
6. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia
7. Cervical lymphatics, the bloodbrain barrier and the immunoreactivity of the brain: A new view
8. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
9. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity
10. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
11. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
12. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
13. + T cell-dependent tumor rejection
14. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
15. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12
16. Induction of antitumor immunity using intercellular adhesion molecule 1 (ICAM-1) transfection in mouse glioma cells
17. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system
18. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
19. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity
20. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
21. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
22. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
23. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
24. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
25. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
26. Retroviral transduction of human dendritic cells with a tumorassociated antigen gene
27. The dendritic cell system and its role in immunogenicity
28. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumorspecific CTLs in vitro
29. Autologous human monocytederived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Thl-biasing cytokines IL-12 and IFN-alpha
30. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4
31. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
32. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines